Regulatory
Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for
Shots: The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM […]readmore